The potential of CAR T cell therapy for prostate cancer

Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of the patient's own T cells so that they specifically recognize and destroy tumour cells. Considerable clinical success has been achieved using this technique in patients with lymphoid malignancies, but clinical studies that investigated treating solid tumours using this emerging technology have been disappointing. A number of developments might be able to increase the efficacy of CAR T cell therapy for treatment of prostate cancer, including improved trafficking to the tumour, techniques to overcome the immunosuppressive tumour microenvironment, as well as methods to enhance CAR T cell persistence, specificity and safety. Furthermore, CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer. Chimeric antigen receptor T cell immunotherapy for prostate cancer has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy; furthermore, new developments could improve the efficacy of chimeric antigen receptor T cell therapy and this treatment could also be applied as focal therapy for this disease.

Automated summary

CAR T cell immunotherapy has shown clinical success in lymphoid malignancies but disappointing results in solid tumors. Improving CAR T cell therapy for prostate cancer could involve enhancing cell trafficking, overcoming the immunosuppressive tumor microenvironment, and enhancing cell persistence, specificity, and safety. Additionally, combining CAR T cell therapy with other treatments like androgen deprivation therapy, radiotherapy, or chemotherapy may increase efficacy and could also be applied as focal therapy for prostate cancer.